Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.KYNB · Entity 7431 | Director · CEO | September 06, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date September 06, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,796 |
Reported balance
After 2026-09-06 transaction · row 1
1 source rowRow 1 · 2026-09-06 · Tax withholding · Disposed 209 · Balance 26,796 F1: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 40 |
Reported balance
Holding disclosure · report date 2026-09-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 40 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2023 Filed Feb 24, 2023 01:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $22.60 | $0.00 |
DisclosureSEC source: 0001209191-23-012430 · doc4.xml · derivative · entry 2 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2033-02-20 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option will vest on March 1, 2024, and the remainder of the options will vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 01:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012430 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,355 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent of the RSUs will vest on March 6, 2024, and the remainder of the RSUs will vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 23:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 734 | $15.80 | $11,597.20 |
DisclosureSEC source: 0001209191-22-062858 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,163 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| December 08, 2022 Filed Dec 10, 2022 00:21 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 382 | $15.79 | $6,031.78 |
DisclosureSEC source: 0001209191-22-060581 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,897 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| September 22, 2022 Filed Sep 26, 2022 20:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 655 | $12.26 | $8,030.30 |
DisclosureSEC source: 0001209191-22-051250 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,279 F1 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 22:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 360 | $12.26 | $4,413.60 |
DisclosureSEC source: 0001209191-22-049224 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,934 F1 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| August 22, 2022 Filed Feb 17, 2023 22:26 UTC Amendment | KYNTRA BIO, INC. FGEN · Entity 7431 | GiftCommon Stock | 1,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010803 · doc5a.xml · nonDerivative · entry 2 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,355 Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 655 | $11.42 | $7,480.10 |
DisclosureSEC source: 0001209191-22-039295 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,294 F1 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. F2 · balance_after: Includes 1,988 shares acquired on May 13, 2022 through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:22 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 360 | $9.50 | $3,420.00 |
DisclosureSEC source: 0001209191-22-035217 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,961 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| May 25, 2022 Filed Feb 2, 2023 22:22 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GiftCommon Stock | 1,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006278 · doc5.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,175 Read SEC document |
| May 25, 2022 Filed Feb 17, 2023 22:26 UTC Amendment | KYNTRA BIO, INC. FGEN · Entity 7431 | GiftCommon Stock | 1,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010803 · doc5a.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,175 Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 23:57 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 655 | $13.31 | $8,718.05 |
DisclosureSEC source: 0001209191-22-021000 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,321 F1 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 22:46 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 1,706 | $12.69 | $21,649.14 |
DisclosureSEC source: 0001209191-22-017653 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,976 F1 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0001209191-22-010459 · doc4.xml · derivative · entry 2 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-13 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option will vest on March 1, 2023, and the remainder of the options will vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010459 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,682 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent of the RSUs will vest on March 6, 2023, and the remainder of the RSUs will vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 22:17 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 517 | $14.97 | $7,739.49 |
DisclosureSEC source: 0001209191-21-071114 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,682 F1 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. F2 · balance_after: Includes 3 shares acquired on November 15, 2021 through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 20:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 620 | $10.18 | $6,311.60 |
DisclosureSEC source: 0001209191-21-057566 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,196 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| August 26, 2021 Filed Aug 31, 2021 00:11 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | PurchaseCommon Stock | 3,100 | $11.53 | $35,743.00 |
DisclosureSEC source: 0001209191-21-053980 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,816 Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 23:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 2,593 | $27.65 | $71,696.45 |
DisclosureSEC source: 0001209191-21-043157 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,716 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. F2 · balance_after: Includes 1,159 shares acquired on May 14, 2021 through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 00:28 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 32,100 | $0.00 Strike: $53.01 | $0.00 |
DisclosureSEC source: 0001209191-21-015013 · doc4.xml · derivative · entry 2 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,100 Underlying: Common Stock · 32,100 shares Expires 2031-02-24 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on March 1, 2022, and the remainder vests in equal amounts quarterly thereafter for the following three years. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 00:28 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015013 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,150 F1 · shares: Represents the grant of restricted stock units. Twenty-five percent of the restricted stock units vest on March 6, 2022, and the remainder vests in equal amounts quarterly thereafter for the following three years. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:51 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $42.08 | $0.00 |
DisclosureSEC source: 0001209191-20-038795 · doc4.xml · derivative · entry 2 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2030-06-22 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vest on June 22, 2021 and the remainder vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:51 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-038795 · doc4.xml · nonDerivative · entry 1 Wettig Thane · CIK 0001815638 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,600 F1 · kind: Represents the grant of restricted stock units. Twenty-five percent of the restricted stock units vest on June 22, 2021, and the remainder vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.